Article
Immunology
Chunyu Liu, Chuanfei Yu, Yalan Yang, Yongfei Cui, Feng Zhang, Lan Wang, Junzhi Wang
Summary: The study developed and validated a reporter gene assay to determine the bioactivity of anti-CTLA-4 mAbs, addressing the challenge faced by quality control labs. The assay demonstrated excellent specificity, accuracy, precision, linearity, and cell passage stability, making it suitable for characterization, batch release control, stability study, and biosimilar assessment of anti-CTLA-4 mAbs.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2021)
Article
Oncology
Y. Nakamura, K. Namikawa, S. Yoshikawa, Y. Kiniwa, T. Maekawa, O. Yamasaki, T. Isei, S. Matsushita, M. Nomura, Y. Nakai, S. Fukushima, S. Saito, T. Takenouchi, R. Tanaka, H. Kato, A. Otsuka, T. Matsuya, N. Baba, K. Nagase, T. Inozume, N. Fujimoto, Y. Kuwatsuka, M. Onishi, T. Kaneko, T. Onuma, Y. Umeda, D. Ogata, A. Takahashi, M. Otsuka, Y. Teramoto, N. Yamazaki
Summary: In a study of advanced mucosal melanoma patients in Japan, it was found that there was no significant difference in efficacy between PD1 and PD1 + CTLA4, but the latter had a higher incidence of immune-related adverse events.
Article
Immunology
Benjamin Mueller, Anne Baerenwaldt, Petra Herzig, Alfred Zippelius, Lara Valeska Maul, Viviane Hess, David Koenig, Heinz Laeubli
Summary: This study characterized the peripheral immune cell subsets in patients receiving anti-PD-1 monotherapy and dual immune receptors blockade, and found differences in CD8(+) T cell subsets between patients with severe immune-related side effects and those with mild irAEs. These changes may serve as biomarkers for early diagnosis of irAEs in the future.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Oncology
Yoshiyasu Umeda, Shusuke Yoshikawa, Yukiko Kiniwa, Takeo Maekawa, Osamu Yamasaki, Taiki Isei, Shigeto Matsushita, Motoo Nomura, Yasuo Nakai, Satoshi Fukushima, Shintaro Saito, Tatsuya Takenouchi, Ryo Tanaka, Hiroshi Kato, Atsushi Otsuka, Taisuke Matsuya, Natsuki Baba, Kotaro Nagase, Takashi Inozume, Takehiro Onuma, Yutaka Kuwatsuka, Noriki Fujimoto, Takahide Kaneko, Masazumi Onishi, Kenjiro Namikawa, Naoya Yamazaki, Yasuhiro Nakamura
Summary: The study found that the combination of radiotherapy (RT) with immune checkpoint inhibitors (ICIs) did not result in a significant survival benefit for patients with mucosal melanoma (MUM), although it may help improve local tumor control and relieve local symptoms.
EUROPEAN JOURNAL OF CANCER
(2021)
Article
Oncology
Megan M. Y. Hong, Saman Maleki Vareki
Summary: Immunotherapy has revolutionized the treatment of advanced cancers by utilizing the immune system to target tumor cells. CTLA-4-targeting agents can release the brakes on the immune system to promote anti-tumor immune responses. While anti-CTLA-4 therapy can confer long-lasting clinical benefits, patient response rates remain relatively low.
Article
Oncology
Monika Semmrich, Jean-Baptiste Marchand, Laetitia Fend, Matilda Rehn, Christelle Remy, Petra Holmkvist, Nathalie Silvestre, Carolin Svensson, Patricia Kleinpeter, Jules Deforges, Fred Junghus, Kirstie L. Cleary, Mimoza Boden, Linda Martensson, Johann Foloppe, Ingrid Teige, Eric Quemeneur, Bjorn Frendeus
Summary: This study demonstrates a highly effective and safe strategy to target CTLA-4 using a vectorized alpha CTLA-4 with strong Treg-depleting and checkpoint-blocking properties. This approach shows promising results in enhancing anti-tumor immunity.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Review
Oncology
Andrea Boutros, Enrica Teresa Tanda, Elena Croce, Fabio Catalano, Marcello Ceppi, Marco Bruzzone, Federica Cecchi, Luca Arecco, Matteo Fraguglia, Paolo Pronzato, Carlo Genova, Lucia Del Mastro, Matteo Lambertini, Francesco Spagnolo
Summary: The anti-LAG3 plus anti-PD-1 combination therapy has been approved as a treatment option for advanced melanoma. This study conducted a systematic review and network meta-analysis comparing different first-line treatment options in terms of progression-free survival, overall response rate, and treatment-related adverse events. The results showed that relatlimab/nivolumab had similar efficacy to ipilimumab/nivolumab but with a better safety profile.
EUROPEAN JOURNAL OF CANCER
(2023)
Review
Oncology
Anna Lorenz, Mateusz Kozlowski, Sebastian Lenkiewicz, Sebastian Kwiatkowski, Aneta Cymbaluk-Ploska
Summary: Melanoma of the vulva and vagina is a rare neoplasm with a poor prognosis. Immunotherapy, a rapidly developing cancer treatment method, has limited effectiveness for this rare type of melanoma.
Article
Oncology
Hikmat H. Assi, Chihunt Wong, Kimberly A. Tipton, Li Mei, Ken Wong, Jennifer Razo, Chanty Chan, Bruce Howng, Jason Sagert, Michael Krimm, Linnea Diep, Andrew Jang, Margaret T. Nguyen, Nicole Lapuyade, Victoria Singson, Ruth Villanueva, Madan Paidhungat, Shouchun Liu, Vangipuram Rangan, Olga Vasiljeva, James W. West, Jennifer H. Richardson, Bryan Irving, Dylan Daniel, Marcia Belvin, W. Michael Kavanaugh
Summary: Using protease-activatable antibody prodrugs (Pb-Tx) to locally inhibit PD-1/PD-L1 can reduce systemic immune toxicity while eliciting potent anti-tumor immune responses.
CANCER IMMUNOLOGY RESEARCH
(2021)
Article
Multidisciplinary Sciences
James A. Hutchinson, Katharina Kronenberg, Paloma Riquelme, Juergen J. Wenzel, Gunther Glehr, Hannah-Lou Schilling, Florian Zeman, Katja Evert, Martin Schmiedel, Marion Mickler, Konstantin Drexler, Florian Bitterer, Laura Cordero, Lukas Beyer, Christian Bach, Josef Koestler, Ralph Burkhardt, Hans J. Schlitt, Dirk Hellwig, Jens M. Werner, Rainer Spang, Barbara Schmidt, Edward K. Geissler, Sebastian Haferkamp
Summary: The study reveals that pre-treatment expansion of CD4(+) effector memory T cells is a risk factor for hepatitis following immune checkpoint blockade therapy, and suggests possibilities for prevention or avoidance. The findings illustrate how clinical reactions after cancer therapy can be shaped by pathogen exposure, leading to therapeutic innovations.
NATURE COMMUNICATIONS
(2021)
Article
Oncology
Katie M. Campbell, Meelad Amouzgar, Shannon M. Pfeiffer, Timothy R. Howes, Egmidio Medina, Michael Travers, Gabriela Steiner, Jeffrey S. Weber, Jedd D. Wolchok, James Larkin, F. Stephen Hodi, Silvia Boffo, Lisa Salvador, Daniel Tenney, Tracy Tang, Marshall A. Thompson, Christine N. Spencer, Daniel K. Wells, Antoni Ribas
Summary: Immune checkpoint inhibitors (ICIs) such as CTLA-4 and PD-1-blocking antibodies have significant effects on tumor immune cell infiltration. In this study, we analyzed molecular datasets from 514 patients with advanced melanoma to explore the features of anti-PD-1 response. We found that prior anti-CTLA-4 therapy is associated with genomic and transcriptomic differences in anti-PD-1 responders, suggesting that the tumor microenvironment plays a role in predicting the response to PD-1 blockade therapy.
Article
Oncology
Yasuhiro Nakamura, Kenjiro Namikawa, Yukiko Kiniwa, Hiroshi Kato, Osamu Yamasaki, Shusuke Yoshikawa, Takeo Maekawa, Shigeto Matsushita, Tatsuya Takenouchi, Takashi Inozume, Yasuo Nakai, Satoshi Fukushima, Shintaro Saito, Atsushi Otsuka, Noriki Fujimoto, Taiki Isei, Natsuki Baba, Taisuke Matsuya, Ryo Tanaka, Takahide Kaneko, Masazumi Onishi, Yutaka Kuwatsuka, Kotaro Nagase, Takehiro Onuma, Motoo Nomura, Yoshiyasu Umeda, Naoya Yamazaki
Summary: This study compared the efficacy of PD-1 and PD-1+CTLA-4 for the treatment of advanced AM in Japanese patients. The results showed no significant differences in ORR, PFS, and OS between the two groups in PSM patients. In NAM patients, the PD-1+CTLA-4 group had significantly higher ORR and longer PFS, and PD-1+CTLA-4 was identified as an independent predictor of favorable PFS in NAM patients.
EUROPEAN JOURNAL OF CANCER
(2022)
Article
Oncology
Julia Lai-Kwon, Sarah Jacques, Matteo Carlino, Naima Benannoune, Caroline Robert, Clara Allayous, Barouyr Baroudjian, Celeste Lebbe, Lisa Zimmer, Zeynep Eroglu, Turkan Ozturk Topcu, Florentia Dimitriou, Andrew Haydon, Serigne N. Lo, Alexander M. Menzies, Georgina Long
Summary: This study investigates the efficacy of a combination therapy strategy involving low-dose ipilimumab (IPI) and an anti-PD1 antibody in advanced melanoma. The results show that the majority of patients who progress following low-dose IPI and subsequently receive IPI 3 mg/kg (IPI3) have a positive response to this treatment. This suggests that the dosage of IPI is critical for certain patients.
EUROPEAN JOURNAL OF CANCER
(2023)
Review
Pharmacology & Pharmacy
Lucia Lisi, Pedro Miguel Lacal, Maria Martire, Pierluigi Navarra, Grazia Graziani
Summary: Immune checkpoint inhibitors have been investigated as an important approach for cancer immunotherapy, but combination therapy may lead to increased immune-related adverse events. The recent development of anti-CTLA-4 probodies and bispecific molecules targeting both CTLA-4 and PD-1 is considered a potential solution to overcome this drawback.
PHARMACOLOGICAL RESEARCH
(2022)
Article
Oncology
Amit Maity, Rosemarie Mick, Ramesh Rengan, Tara C. Mitchell, Ravi K. Amaravadi, Lynn M. Schuchter, Daniel A. Pryma, Dana M. Patsch, Alisha P. Maity, Andy J. Minn, Robert H. Vonderheide, John N. Lukens
Summary: This study reports the final full clinical analysis of a phase I trial of radiation with ipilimumab in patients with melanoma. Radiotherapy followed by ipilimumab was well tolerated and yielded a response rate that compares favorably to ipilimumab alone. The recommended dose for subsequent phase 2 trials was 8 Gy x 3 doses, based on these results.
Article
Gastroenterology & Hepatology
Jeremy L. Humphris, Ann-Marie Patch, Katia Nones, Peter J. Bailey, Amber L. Johns, Skye Mckay, David K. Chang, David K. Miller, Marina Pajic, Karin S. Kassahn, Michael C. J. Quinn, Timothy J. C. Bruxner, Angelika N. Christ, Ivon Harliwong, Senel Idrisoglu, Suzanne Manning, Craig Nourse, Ehsan Nourbakhsh, Andrew Stone, Peter J. Wilson, Matthew Anderson, J. Lynn Fink, Oliver Holmes, Stephen Kazakoff, Conrad Leonard, Felicity Newell, Nick Waddell, Scott Wood, Ronald S. Mead, Qinying Xu, Jianmin Wu, Mark Pinese, Mark J. Cowley, Marc D. Jones, Adnan M. Nagrial, Venessa T. Chin, Lorraine A. Chantrill, Amanda Mawson, Angela Chou, Christopher J. Scarlett, Andreia V. Pinho, Ilse Rooman, Marc Giry-Laterriere, Jaswinder S. Samra, James G. Kench, Neil D. Merrett, Christopher W. Toon, Krishna Epari, Nam Q. Nguyen, Andrew Barbour, Nikolajs Zeps, Nigel B. Jamieson, Colin J. McKay, C. Ross Carter, Euan J. Dickson, Janet S. Graham, Fraser Duthie, Karin Oien, Jane Hair, Jennifer P. Morton, Owen J. Sansom, Robert Gruetzmann, Ralph H. Hruban, Anirban Maitra, Christine A. Iacobuzio-Donahue, Richard D. Schulick, Christopher L. Wolfgang, Richard A. Morgan, Rita T. Lawlor, Borislav Rusev, Vincenzo Corbo, Roberto Salvia, Ivana Cataldo, Giampaolo Tortora, Margaret A. Tempero, Oliver Hofmann, James R. Eshleman, Christian Pilarsky, Aldo Scarpa, Elizabeth A. Musgrove, Anthony J. Gill, John V. Pearson, Sean M. Grimmond, Nicola Waddell, Andrew V. Biankin
Article
Endocrinology & Metabolism
Anton M. F. Kalsbeek, Eva K. F. Chan, Judith Grogan, Desiree C. Petersen, Weerachai Jaratlerdsiri, Ruta Gupta, Ruth J. Lyons, Anne-Maree Haynes, Lisa G. Horvath, James G. Kench, Phillip D. Stricker, Vanessa M. Hayes
Review
Gastroenterology & Hepatology
G. H. van Ramshorst, S. O'Shannassy, W. E. Brown, J. G. Kench, M. J. Solomon
COLORECTAL DISEASE
(2018)
Article
Biochemistry & Molecular Biology
Ruth Pidsley, Mitchell G. Lawrence, Elena Zotenko, Birunthi Niranjan, Aaron Statham, Jenny Song, Roman M. Chabanon, Wenjia Qu, Hong Wang, Michelle Richards, Shalima S. Nair, Nicola J. Armstrong, Hieu T. Nim, Melissa Papargiris, Preetika Balanathan, Hugh French, Timothy Peters, Sam Norden, Andrew Ryan, John Pedersen, James Kench, Roger J. Daly, Lisa G. Horvath, Phillip Stricker, Mark Frydenberg, Renea A. Taylor, Clare Stirzaker, Gail P. Risbridger, Susan J. Clark
Article
Cell Biology
Lars Egevad, Brett Delahunt, Daniel M. Berney, David G. Bostwick, John Cheville, Eva Comperat, Andrew J. Evans, Samson W. Fine, David J. Grignon, Peter A. Humphrey, Jonas Hornblad, Kenneth A. Iczkowski, James G. Kench, Glen Kristiansen, Katia R. M. Leite, Cristina Magi-Galluzzi, Jesse K. McKenney, Jon Oxley, Chin-Chen Pan, Hemamali Samaratunga, John R. Srigley, Hiroyuki Takahashi, Lawrence D. True, Toyonori Tsuzuki, Theo van der Kwast, Murali Varma, Ming Zhou, Mark Clements
Article
Endocrinology & Metabolism
Hui-Ming Lin, Brian Y. Lee, Lesley Castillo, Calan Spielman, Judith Grogan, Nicole K. Yeung, James G. Kench, Phillip D. Stricker, Anne-Maree Haynes, Margaret M. Centenera, Lisa M. Butler, S. Martin Shreeve, Lisa G. Horvath, Roger J. Daly
Article
Urology & Nephrology
Kae Jack Tay, Mahul B. Amin, Sangeet Ghai, Rafael E. Jimenez, James G. Kench, Laurence Klotz, Rodolfo Montironi, Satoru Muto, Ardeshir R. Rastinehad, Baris Turkbey, Arnauld Villers, Thomas J. Polascik
WORLD JOURNAL OF UROLOGY
(2019)
Article
Genetics & Heredity
Shalima S. Nair, Phuc-Loi Luu, Wenjia Qu, Madhavi Maddugoda, Lily Huschtscha, Roger Reddel, Georgia Chenevix-Trench, Martina Toso, James G. Kench, Lisa G. Horvath, Vanessa M. Hayes, Phillip D. Stricker, Timothy P. Hughes, Deborah L. White, John E. J. Rasko, Justin J. -L. Wong, Susan J. Clark
EPIGENETICS & CHROMATIN
(2018)
Article
Multidisciplinary Sciences
James M. Henderson, Natasa Polak, Jinbiao Chen, Ben Roediger, Wolfgang Weninger, James G. Kench, Geoffrey W. McCaughan, Hui Emma Zhang, Mark D. Gorrell
SCIENTIFIC REPORTS
(2018)
Article
Gastroenterology & Hepatology
Deepak Raj, Ming-Hsin Yang, David Rodgers, Eric N. Hampton, Julfa Begum, Arif Mustafa, Daniela Lorizio, Irene Garces, David Propper, James G. Kench, H. M. Kocher, Travis S. Young, Alexandra Aicher, Christopher Heeschen
Article
Oncology
Alison Y. Zhang, Karen Chiam, Ygal Haupt, Stephen Fox, Simone Birch, Wayne Tilley, Lisa M. Butler, Karen Knudsen, Clay Comstock, Krishan Rasiah, Judith Grogan, Kate L. Mahon, Tina Bianco-Miotto, Carmela Ricciardelli, Maret Bohm, Susan Henshall, Warick Delprado, Phillip Stricker, Lisa G. Horvath, James G. Kench
INTERNATIONAL JOURNAL OF CANCER
(2019)
Article
Gastroenterology & Hepatology
Ashika D. Maharaj, Liane Ioannou, Daniel Croagh, John Zalcberg, Rachel E. Neale, David Goldstein, Neil Merrett, James G. Kench, Kate White, Charles H. C. Pilgrim, Lorraine Chantrill, Peter Cosman, Andrew Kneebone, Lara Lipton, Mehrdad Nikfarjam, Jennifer Philip, Charbel Sandroussi, Peter Tagkalidis, Richard Chye, Koroush S. Haghighi, Jaswinder Samra, Sue M. Evans
Article
Urology & Nephrology
Judith Grogan, Ruta Gupta, Kate L. Mahon, Phillip D. Stricker, Anne-Maree Haynes, Warick Delprado, Jennifer Turner, Lisa G. Horvath, James G. Kench
Article
Oncology
A. Y. Zhang, J. S. Grogan, K. L. Mahon, K. Rasiah, P. Sved, D. R. Eisinger, J. Boulas, A. Vasilaris, S. M. Henshall, P. D. Stricker, J. G. Kench, L. G. Horvath
ANNALS OF ONCOLOGY
(2017)
Letter
Medical Laboratory Technology
Brett Delahunt, David J. Grignon, Hemamali Samaratunga, John R. Srigley, Katia R. M. Leite, Glen Kristiansen, Andrew J. Evans, James G. Kench, Lars Egevad
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
(2017)